Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 4, 1994 - Issue 12
Submit an article Journal homepage
9
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Central & Peripheral Nervous System: Overview D1 selective and mixed D1/D2 dopaminergic compounds: Structural diversity and recent advances

Michael T Klimas Zeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE, 19897, USA
Pages 1493-1507 | Published online: 03 Mar 2008

References to Primarv Literaturess

  • ERESHEFSKY L, TRAN-JOHNSON TK, WATANABE MD: Pathophysiologic basis for schizophrenia and the effi-cacy of antipsychotics. Clin. Mann. (1990) 9: 682–707.
  • JOSE PA, RAYMOND JR, BATES MD, APERIA A, FEWER RA, CAREY RM: The renal dopamine receptors. J. Am. Soc. Nephrol. (1992) 2: 1265–1278.
  • REVESZ L, MEIGEL H: 186. Design and synthesis of a potential dopamine D-1 antagonist. Hely. Chtm. Acta (1988) 71: 1697–1703.
  • MONTASTRUC JL: Recent advances in the clinical phar-macology of Parkinson's disease. Therapie (1991) 46: 293–303.
  • COSTENTIN J: Brain dopamine receptors. interactions between Di and 132 receptors, and dopamine mediated behaviour. Tberapie (1991) 46: 269–282.
  • CHIODO LA, BUNNEY BS: Possible mechanisms bywhich repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J. Neurosci. (1985) 5: 2539–2544. Atypical antipsychotic's electrophysiological profile, both acute and chronic.
  • AZORIN JM, DASSA D, JALFRE M: The atypical neuroleptic concept Encephale (1992) 18: 453–457. Modulation and/or enhancement of antipsychotic mechanism of action by 000-D2 dopaminergic receptor affinities.
  • 101110 LC, BARNETT A, LEITZ FH, HOUSER VP, KORDUBA CA: SCH23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. E. Ther. (1983) 226: 462.
  • CHRISTENSEN AV, ARNT J, HYTTEL J, LARSEN J-J, SVEND-SON 0: Pharmacological effects of a specific dopamine 1)-i antagonist SCH23390 in comparison with neurolep-tics. Life Sci. (1984) 34: 1529.
  • COFFIN VL, LATRANYI MB, CHIPKIN RE: Acute ex-trapyramidal syndrome in cebus monkeys: develop-ment mediated by dopamine Di but not Di receptors. J. Pharmacol. Exp. Then (1989) 249: 1.
  • BREESE GR, CRISWELL HE, MUELLER RA: Evidence that lack of brain dopamine during development can in-crease the susceptibility for aggression and self-injuri-ous behavior by influencing Di-dopamine receptor function. Prog. Neuru-Psychopharmacol Biol. Psychiauy (1990) 14: S65–S80.
  • GAO Y, RAM VJ, CAMPBELL A, KULA NS, BALDESSARINIRJ, NEUMEYER JL: Synthesis and structural requirements of n-substituted norapomorphines for affinity and ac-tivity at dopamine D-1, D-2, and agonist receptor sites in rat brain. J. Med. Chem. (1990) 33: 39–44. Functional interactions between Di and D2 subtypes of dopaminer-gic systems.
  • BENINGER RJ, MAZURSKI EJ, HOFFMAN DC: Receptor subtype-specific dopaminergic agents and uncondi-tioned behavior. Pol. J. Pharmacol. Pharm. (1991) 43: 507–528.
  • DAVIS DA, DEPAULIS T, JANOWSKY A, SMITH HE: Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J. Med. Chem. (1990) 33: 809–814.
  • NIELSEN EB, ANDERSEN PH: Dopamine receptor occu-pancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine Di receptor antagonists. Eur.J.Pharmacol. (1992) 219: 35–44.
  • GERFEN CR: The neostriatal mosaic multiple levels of compartmental organization. J. Neural. Transm. Suppl. (1992) 36: 43–59.
  • LIEGEOIS J-FF, BRUHWYLER J, DAMAS J, NGUYEN TP, CHLEIDE EMG, MERCIER MGA, ROGISTER FA, DELARGE JE: New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study. J. Med. Chem. (1993) 36: 2107–2114.
  • BRUHWYLER J, LlEGEOIS JF, CIILEIDE E, ROGISTER F, DAMAS J, DELARGE J, MERCIER M: Comparitive study of typical neuroleptks, clozapine and newly synthesized clozapine-analogues: correlations between neuro-chemistry and behaviour. Behav. Pharmacol. (1992) 3: 567–579.
  • GERLACH J: New antipsychotics: classification, efficacy, and adverse effects. Schizophr. Bull. (1991) 17: 289–309.
  • MELTZER HY, GUDELSKY GA: Dopantinergic and sero-tonergic effects of clozapine. Implications for a uniqueclinical profile. Arzneimittelforschung (1992) 42: 268–272. Clozapine's expanded efficacy and reduced propensity for ex-trapyramidal side effects.
  • SELF DW, STEIN L: Receptor subtypes in opioid andstimulant reward. Pharmacol. Toxicol. (1992) 70: 87–94.
  • GERSON SL, MELTZER H: Mechanisms of clozapine-in-duced agranulocytosis. Drug Safety (1992) 7: 17–25.
  • WISE LD, HEFFNER TG: Antipsychotics: Annual Reports in Medicinal Chemistry 26 McCall JM (Ed) . New York, Aca-demic Press, 1991, pp 53–62.
  • CRISWELL HE, MUELLER RA, BREESE GA: Clozapine an-tagonism of D-1 and D-2 dopamine receptor-mediated behaviors. Eur. J. Parmacol. (1989) 159: 141–147.
  • JANN MW: Clozapine. Pharmacotherapy (1991) 11: 179–195.
  • GERLACH J, HANSEN L: Clozapine and Di/D2 antagonismin extrapyramidal functions. Br. J. Psychiatry(1992) 160:34-37. Clozapine and other antipsychotics receptor occupancy percentages at therapeutic doses.
  • MELTZER HY: Clinical studies on the mechanism ofaction of clozapine: the dopamine-serotonin hypothe-sis of schizophrenia. Psychopharmacol. (1989) 99: S18–S27.
  • BALDESSARINI RJ, HUSTON-LYONS D, CAMPBELL A, MARSH E, COHEN BM: Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br.J. Psychiatry (1992) 12–16.
  • MOORE NA, TYE NC, AXTON MS, RISIUS FC: The behav-ioral pharmacology of oianzapine, a novel 'atypical' antipsychotic agent J. Pharmacol. Exp. Ther. (1992) 262: 545–551.
  • ROBINSON RL, VISSCHER GE, ROBERTS SA, ENGSTROM RG, HARTMAN HA, BALLAD FH: Generalized phos-pholipidosis induced by an amphiphilic cationic psy-chotropic drug. Tax. Pathot (1985) 13: 335–348.
  • CHAKRABARTI.IK, HOTTEN TM, PULLAR IA, STEGGLES DJ: Synthesis and pharmacological evaluation of CNS ac-tivities of [1,2,31triazolo[4,5-b]-, imidazolf4,5-b)[1,5]-, and pyrido[2,3-b][1,5]benzodiazepines. 10-piperaziny1-4H-1,2,3-triazolo[4,5-1,1[1,5]benzodiazepines with neuroleptic activity. J. Med. Chem. (1989) 32: 2375–2381.
  • HINO K, NAGAI Y, UNO H, MASUDA Y, OKA M, KARASAWA T: A novel class of potential central nervous system agents. 3-phenyl-2-(1-piperazinyl) -511-1-ben-zazepines. J. Med. Chem. (1988) 31: 107–117.
  • LEES AJ: Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin. Pharm.acol (1993)7: 121–128.
  • MARTIN LP, COX RF, WASZC ZAK BL: Efficacy and potency comparisons among aporphine enantiomers: effects on dopamine neurons in substantia nigra of rat. Neuro-pharmacol. (1990) 29: 135–143.
  • SCHAUS JM, TITUS RD, FOREMAN MM, MASON NR, TRUEX LL: Aporphines as antagonists of dopamine 0-1 recep-tors. J. Med. Chem. (1990) 33: 600–607.
  • NEUMEYER JL, GAO Y, KULA NS, BALDESSARINI RJ: Syn-thesis and dopamine receptor affinity of (R) -(-) -2-fluoro-n-m-propylnorapomorphine: a highly potent and selective dopamine Di agonist J. Med. Chem. (1990) 33: 3122–3124.
  • SEILER MP, MARKSTEIN R, WALKINSHAW MD, BOELSTERLIJJ: Characterization of dopamine receptor subtypes by comparative structure-activity relationships: dopami-nomimetic activities and solid state conformation of mortohydroxy-1,2,3,4,4a,5,10,10a-octahydrobenzWq uinolines and its implications for a rotamer-based dopamine receptor modeL Mol. Pharmacol. (1989) 35: 643–651.
  • CRAIG JC, TORKELSON SM, FINDELL PR, WEINER RI: Syn-thesis and dopaminergk activity of 2-substituted octa-hydrobenzo[f]quinolines. J. Med. Chem. (1989) 32: 961–968.
  • NISOL1 E, TONELLO C, IMHOF R, SCHERSCHLICHT R, DAPRADA M, CARRUBA MO: Neurochemical and behav-ioural evidence that Ro 41-9067 is a selective presynap-tic dopamine receptor agonist J. Pharmacol. Exp. Ther. (1993) 266: 97–105.
  • MTH FR DD, URETSKY NJ: Dopamine agonists and CNS receptors. In: Advances in CNS drug-receptor interactions. JAI Press Inc, 1991, pp 75–129.
  • LADD DL, WEINSTOCK J, WISE M, GESSNER GW, SAWYER JL, FLAIM RE: Synthesis and dopaminergic binding of 2-aryldopamine analogs: phenethylamines, 3-ben-zazepines, and 9-(aminomethyl) fluorenes. J. Med. Chem. (1986) 29: 1904–1912.
  • IWATSUKI K, REN L-M, CHIBA S: Effects of YM435, a novel dopamine di receptor agonist, on pancreatic exocrine secretion on anesthetized dogs. Eur. J. Parmacol. (1992) 218: 237–241. Tetrahydroisoquinoline containing compounds with selective, high affinity at the Di receptor subtype.
  • O'BOYLE KM, GA1TANOPOULOS DE, BRENNER M, WAD-DINGTON JL: Agonist and antagonist properties of ben-zazepine and thienopyridine derivatives at the Di dopamine receptor. Neuropharmacol. (1989) 28: 401–405.
  • ANDERSEN PH, NIELSEN EB, SCHEEL-KRUEGER J, JANSEN JA, HOHLWEG R: Thienopyridlne derivatives identified as the first selective, fullefficacy, dopamine Di receptor agonists. Eur. J. Parmacol. (1987) 137: 291–292.
  • MOTTOLALA DM, BREWSTER WE, COOK LL, NICHOLS DE, MAILMAN RB: Dihydrexidine, a novel full efficacy Di dopamine receptor agonist J. Pharmacol. Exp. Ther. (1992) 262: 383–393.
  • KOHLI JD, HORN PT, GLOCK D, BREWSTER WK, NICHOLS DE: Dfftydrexidine: a new potent peripheral dopamine Di receptor agonist Eur.J. Parrnacol. (1993) 235: 31–35.
  • BREWSTER WE, NICHOLS DE, RIGGS RM, marroLA DM, LOVENBERG TVC7, LEWIS MH, MAILMAN RB: Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenan thridine: a highly potent selective dopamine Di full agonist J. Med. Chem. (1990) 33: 1756–1764.
  • TAYLOR JR, LAWRENCE MS, REDMOND Jr DE, ELSWORTHJD, ROTH RH, NICHOLS DE, MAILMAN RB: Dihydrexidine, a full dopamine Di agonist, reduces MPTP-induced parkinsonism in African green monkeys. Eur.J. Parma-col. (1991) 199: 387–388.
  • RIDDALL DR: A comparison of the selectivities of5CH23390 with BW737039 for Di, D2 and 5-HT2 binding sites both in vitro and in vivo. Fur. J. Parmacol. (1992) 210: 279–284.
  • KERKMAN DJ, ACKERMAN M, ARTMAN LD, MACKENZIE RG, JOHNSON MC, BEDNARZ L, MONTANA W, ASIN KE, STAMPFLI H, KEBABIAN JW: A-69024: a non-benzazepine antagonist with selectivity for the dopamine 1)-1 recep-tor. Fur. Parmacol. (1989) 166: 481–491.
  • VAUQUELIN G, DEKEYSER J, KANYINDA B, VANHAELEN M: (+-) Tetrahydroanisocycline and (+-) tetrahydropal-matine binding to Di and 132 dopaminergic receptors In human putamen. Neurocbem. Int. (1989) 15: 321–324.
  • PEITERSSON I, GUNDERTOFTE K, PALM J, LILJEFORS T: A study on the contribution of the 1-phenyl substituent to the molecular electrostatic potentials of some ben-zazdepines in relation to selective dopamine D-1 recep-tor activity.]. Med. Chem. (1992) 35: 502–507.1-Pheny1-2,3,4,5-tetrahydro-1H-3-benzazepines, the most important substructural design advancement in distinguishing Di and D2 affinity and pharmacology.
  • ANDERSEN PH, GRONVALD FC, HOHLWEG R, HANSEN LB, GUDDAL E, BRAESTRUP C, NIELSEN EB: NNC-112, NNC-687 and NNC-756, New selective and highly potent dopamine Di receptor antagonists. Fur. j Parmacol. (1992) 219: 45–52.
  • BARNETT A, MCQUADE RD, TEDFORD C: Highlights of Di dopamine receptor antagonist research. Neurochem. Int. (1992) 20: 119S–122S.
  • BERGER JG, CHANG WK, CLADER JW, et al: The design and synthesis of a series of conformationally restricted analogs of the selective dopamine Di antagonist. SC1123390 Gordon Research Conference on Medicinal Chemistry. 1990. (UnPub)
  • CHIPKIN RE, IORIO LC, COFFIN VL, MCQUADE RD, BER-GER JG, BARNETT A: Pharmacological profile of SCH39166: a dopamine Di selective ben-zonaphthazepine with potential antipsychotic activity. J. Pharmacol. Exp. Ther. (1988) 247: 1093–1102.
  • HOLCSLAW U, BECK TR: Clinical experience with intra-venous fenoldopam. Am.J. Hypertens. (1990) 3: 120S–125S.
  • MURPHY MB, ELLIOTT WJ: Dopamine and dopamine receptor agonists in cardiovascular therapy. Crit. Care Med. (1990) 18: S14–S18.
  • BAINDUR N, TRAN M, NIZNIK HB, GUAN HC, SEEMAN P, NEUMEYER JL: (+-) -3-Ally1-7-halo-8-hyciroxy-1-pheny1-2,3,4,5-tetrahydro-1H-3-bemazepines as selective high affinity Di dopamine receptor antagonists: synthesis and structure-activity relationship. J. Med. Chem. (1992) 35: 67–72.
  • GENTLES RG, MIDDLEMISS ID, PROCTOR GR, SNEDDON All: Bridged-ring nitrogen compounds. part 10. Synthe-sis of bridged 3-lben727epine derivatives as conforma-tionally restricted dopamine analogues. J. Chem. Soc. Perkin. Trans. (1991) 1423–1431.
  • CHARIFSON PS, BOWEN JP, WYRICK SD, HOFFMAN AJ,CORY M, MCPHAIL AT, MAILMAN RB: Conformational analysis and molecular modeling of 1-phenyl-, 4- phenyl-, and 1-benzy1-1,2,3,4-tetrahydroisoquinolines as Di dopamine receptor ligands. J. Med. Chem, (1989) 32: 2050–2058.
  • PEI1E.RSSON I, LILJEFORS T, BOGESO K: Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.]. Med. Chem. (1990) 33: 2197–2204.
  • ALKORTA I, VILLAR HO, PEREZ JJ: Comparison of meth-ods to estimate the free energy of solvation: importance In the modulation of the affinity of 3-benzazepines for the Di receptor. J. Comp. Chem. (1993) 14: 620–626.
  • TUPPER DE, PULLAR IA, CLEMENS JA, FAIRHURST J, RISIUS FC, Timms GH, WEDLEY S: Synthesis and dopamine antagonist activity of 2-thioether derivatives of the ergoline ring system. Med. Chem. (1993) 36: 912–918.
  • SEILER MP, HAGENBACH A, WUTHRICH H-J, MARKSTEINR:Trans-hexahydroindolo[4,3-12]phenanthridines('benzergolines'), the first structural class of potent and selective dopamine Di receptor agonists lacking a catechol group. J. Med. Chem. (1991) 34: 303–307, Annulation of a phenyl ring onto an ergoline framework to produce highly selective Di agonists without a catechol functionality.
  • TSUI JKC, WOLTERS EC, PEPPARD RF, CALNE DB: A dou- ble-blind, placebo-controlled, dose-ranging study to Investigate the safety and efficacy of CY208-243 in patients with Parkinson's disease. Neurol. (1989) 39: 856.
  • CRIDER AM, ANDERSEN PH, CRUSE SF, GHOSH D, HAR- PALANI A: 3-Phenylpyrrolidines: synthesis and evalu-ation of the in vitro binding affinity at Di and 132 receptors. EurJ. Med. Chem. (1992) 27: 407–411.
  • MORI N, ISHIHARA H, MATSUOKA T, SAITO M, HOSHIKOT, YONEDA N, SUDA S, YAMANDA M, SHINO M, HAMAN° S: Pharmacology of E4101, a novel, selective and orally active DA-1 dopamine receptor agonist. Eur.J.Parmacol. (1990) 183: 1049. High affinity Di agonists with the 3,4-diaryl pyrroolidine substruc-ture.
  • DEBOER T, BERENDSEN H, BROEKKAMP CLE, VRIJMOED-DEVRIES MC, VOS RME, TONNAER JADM, VANDELFT AML: ORG-5222. Drugs Future (1993) 18: 1117–1123.
  • SMITH GW, FARMER JB, INCE F, MATH K, MITCHELL PD, NAYA I, SPRINGTHORPE B: FPL 63012AR: A potent Di-re-ceptor agonist- Br.] Pharmacol. (1990) 100: 295–300.
  • IZENWASSER S, KATZ JL: Differential efficacies of dopamine Di receptor agonists for stimulating adenylyl cyclase in squirrel monkey and rat. Eur. J. Parmacol. -Molec. Pharm. (1993) 246: 39–44.
  • KEBABIAN JW, DENINNO MP, SCHOENLEBER R, MACKEN-ZIE R, BRITTON DR, ASIN KE: A68930: a potent agonist specific for the dopamine Di receptor. Neurochem. Int. (1992) 20: 157S–160S.
  • DENINNO MP, SCHOENLEBER R, ASIN KE, MACKENZIE R,KEBABIAN JW: (1R,3S) -1-(Aminomethyl) -3,4-dihydro-5,6-dihydroxy-3-pheny1-1H-2-benzopyran: a potent and selective Di agonist. J. Med. Chem. (1990) 33: 2948–2950.
  • DENINNO MP, SCHOENLEBER R, PERNER RJ, LUEWSKI L,ASIN KE, BRITTON DR, MACKENZIE R, KEBABIAN JW: Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl) -3,4-dihydro-5,6-dihydroxy-lh-2-ben zopyrans: characterization of an auxiliary binding re-gion in the Di receptor. J. Med. Chem. (1991) 34: 2561–2569. High affinity Di agonists with the 1-aminomethy1-3-phenyl isochro-man substructure and related compounds.
  • DENINNO MP, SCHOENLEBER R, MACKENZIE R, BRITTON DR, ASIN ICE, BRIGGS C, TRUGMAN JM, ACKERMAN M, ARTMAN L, BEDNARZ L, BHATT R, CURZON P, GOMEZ E, KANG CH, STITTSWORTH J, KEBABIAN JW: A68930: A potent agonist selective for the dopamine Di receptor. Eur. J. Parmacol. (1991) 199: 209–219.
  • KUKLA MJ, BLOSS JL, BROUGHAM LR: Use of the buta-clamol template in a search for antipsychotic agents with lessened side effects. J. Med. Chem. (1979) 22: 401–406.
  • CODY V, FROIMOWITZ M, BUTACLAMOL: Absolute con-figuration, crystal and molecular conformation. J. Ctyst. Spectrosc. Res. (1990) 20: 347–353.
  • HUMBER LG, BRUDERLEIN FT, PHILIPP AH, GOTZ M, VOITH K: Mapping the dopamine receptor. 1. Features derived from modifications in ring e of the neuroleptic butaciamoL J. Med. Chem. (1979) 22: 761–767.
  • VOITH K, BRUDERLEIN FT, HUMBER LG: Neuroleptics related to butaclamoL Synthesis and some psychophar-macological effects of a series of 30 aryl analogues. I Med. Chem. (1978) 21: 694–698. References to Patent Literature

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.